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Summary. During the first decade of the 21st century,
IgG4-related disease (IgG4-RD), a fibroinflammatory
condition occurring at multiple sites of the body, has
been newly recognized. As indicated by its name,
elevation of IgG4 in the serum and tissue is a common
denominator of IgG4-RD. Since the observation that
many patients suffering from autoimmune pancreatitis
(AIP), a specific type of chronic pancreatitis, had
elevated serum levels of IgG4, it was reported that these
patients also had increased numbers of IgG4-positive
cells in the inflamed pancreatic tissue. In 2003, it was
noted that a significant proportion of the AIP patients
had a variety of extrapancreatic fibroinflammatory
lesions, and that AIP therefore was the pancreatic
manifestation of a systemic disease. Among these
extrapancreatic manifestations, the extrahepatic bile
ducts, salivary glands, thyroid, lymph nodes and
retroperitoneum were most frequently reported, and
infiltration of the tissue with IgG4-positive cells was
also noted at these sites. During the following years, a
multitude of other conditions have been added to the
spectrum of IgG4-RD. While some of these organ
manifestations were once believed to represent diseases
on their own, others have been included under the
umbrella of "multifocal fibrosclerosis". Biopsies or
resection specimens from affected organs in IgG4-RD
reveal several common microscopic features irrespective
of the site of the lesion. Cellular and storiform fibrosis,
lymphoplasmacytic infiltration, increased numbers of
IgG4-positive cells and obliterative phlebitis are among
the most characteristic histological changes in IgG4-RD.
The detailed etiology, pathophysiology, epidemiology
and clinical long-term outcome have at present yet to be
fully elucidated. This paper focuses on the microscopic
features, diagnosis and differential diagnosis of the
different organ manifestations of IgG4-RD, and the
current concepts of its pathogenesis will also be
addressed. 
Key words: IgG4-related disease, Obliterative phlebitis,
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Introduction
Historically, the concept of IgG4-related disease
(IgG4-RD) was preceded by the discovery of
autoimmune pancreatitis (AIP) as a new and distinct
type of chronic pancreatitis. In 1995, Yoshida and
coworkers (Yoshida et al., 1995) coined this term, but
the main features of AIP have likely been described
already by Ball et al. in 1950 and by Sarles et al. in 1961
(Ball et al., 1950; Sarles et al., 1961). In 1991, the
histopathology of two cases of “lymphoplasmacytic
sclerosing pancreatitis with cholangitis” were reported,
which later were found to also represent AIP
(Kawaguchi et al., 1991). Histologic criteria for
distinguishing AIP from the most common type of
chronic pancreatitis in western countries, alcoholic
chronic pancreatitis, were established in 1997 (Ectors et
al., 1997; Klöppel et al., 2004). During the last decade,
Asian and Western research groups established criteria
for the diagnosis of AIP (Japan Pancreas Society, 2002;
Chari et al., 2006, 2009; Kim et al., 2006; Otsuki et al.,
2008; Okazaki et al., 2009). 
In 2003, Kamisawa et al. reported 21 AIP patients
whom they had followed and treated. Seven of these
patients had other autoimmune diseases: two had
sclerosing cholangitis, two retroperitoneal fibrosis, two
rheumatoid arthritis and one had Sjögren’s syndrome,
and he concluded that AIP was a systemic autoimmune
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disease and termed it IgG4-related systemic disease
(Kamisawa et al., 2003a,b). However, for several years it
had been noted at microscopy, that AIP is a
heterogeneous disease, and at the consensus conference
on AIP in Honolulu in november 2009, it was agreed
that the type of AIP formerly called lymphoplasmacytic
sclerosing pancreatitis should be labeled type 1 AIP,
while the type formerly designated as idiopathic duct-
centric chronic pancreatitis would be called type 2 AIP
(Notohara et al., 2003; Zamboni et al., 2004; Deshpande
et al., 2006; Chari et al., 2010). Type 1 AIP is one of the
main manifestations of IgG4-RD, while type 2 AIP is
associated with inflammatory bowel disease and does
not belong to the IgG4-RD entity (Chari et al., 2010;
Klöppel et al., 2010; Sah et al., 2010; Deshpande et al.,
2011; Detlefsen et al., 2011, 2012; Maire et al., 2011).
Names formerly used for IgG4-RD are "IgG4-related
autoimmune disease", "IgG4-associated multifocal
systemic fibrosis", "IgG4-related sclerosing disease",
"Hyper-IgG4 disease", "systemic IgG4 plasmacytic
syndrome" (SIPS), "IgG4-related multi-organ
lymphoproliferative syndrome" (IgG4-MOLPS) and
"IgG4-associated disease" (Kamisawa et al., 2003b,
2004, 2006b; van der Vliet and Perenboom, 2004; Neild
et al., 2006; Zen et al., 2007b; Masaki et al., 2009; Geyer
et al., 2010; Yamamoto et al., 2010). However, there is
international consensus on using the unifying term IgG4-
RD (Stone et al., 2012a; Umehara et al., 2012a).
However, as our knowledge of this disease and
particularly its pathogenesis increases, the name will
likely change to a more specific name at some point in
the future (Khosroshahi et al., 2011b). 
This review gives an overview of the microscopic
features of IgG4-RD. The pathogenesis, diagnosis and
differential diagnosis of this evolving rheumatologic
disease are also discussed.
IgG4-related disease: general features and diagnosis
IgG4-RD: a systemic condition
The number of conditions which are part of IgG4-
RD has increased immensely, and the main
manifestations are given in Figure 1 and Table 1. Since
many of the organ manifestations of IgG4-RD are also
affected in multifocal fibrosclerosis, it has been
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Fig. 1. Schematic illustration of the relationship between the IgG4-related type of autoimmune pancreatitis (AIP), other manifestations of IgG4-related
disease (IgG4-RD), and non-IgG4-related AIP.
suggested that there may be an overlap of this disease,
particularly of Riedel’s thyroiditis, and IgG4-RD
(Comings et al., 1967; Dahlgren et al., 2010;
Khosroshahi and Stone, 2011). However, as is known
particularly from the pancreas and bile ducts,
lymphoplasmacytic lesions similar to IgG4-RD but
negative for IgG4 and with slightly different histology
are common. Therefore, this issue should be addressed
in future studies.
Histological features of IgG4-RD
The main histological features of IgG4-RD have
initially been described in type 1 AIP patients: 
A) A prominent infiltration of lymphocytes and
plasma cells in the tissue (Yoshida et al., 1995; Ectors et
al., 1997; Notohara et al., 2003; Zamboni et al., 2004).
B) A characteristic type of lymphoplasmacytic,
cellular fibrosis, named "storiform" or "swirling" fibrosis
(Fig. 2A) (Kamisawa et al., 2003c; Notohara et al., 2003;
Zamboni et al., 2004). The term "storiform" means that
the fibrotic fascicles of fibroblasts and myofibroblasts
are arranged in a cartwheel-like pattern.
C) Evidence of obliterative phlebitis, meaning
inflammation of the veins in the tissue (phlebitis) (Fig.
2B) (Kamisawa et al., 2003c; Notohara et al., 2003;
Zamboni et al., 2004). It seems that the phlebitis begins
at the periphery of the venous wall and later spreads
through the wall, involving also the central part. The
most characteristic lesions are those showing further
increase of inflammation and fibrosis in the venous wall,
resulting in stenosis or obstruction of the lumen. 
D) Abundant infiltration of IgG4-positive plasma
cells (Fig. 2C) in the respective organ (Kamisawa et al.,
2003b; Deshpande et al., 2005). To avoid overdiagnosis
of IgG4-RD, due to the fact that the mere infiltration
with IgG4-positive cells can occur in many other
diseases than IgG4-RD, it is important to employ both a
cut-off for the number of infiltrating IgG4-positive cells
and a ratio of IgG4- over IgG-positive cells (Fig. 2C-D).
These ratios vary, dependent on the affected organ (see
below) (Deshpande et al., 2012). However, a cut-off of
10 IgG4-positive cells/high power field (HPF) and a
ratio of more than 40% has been recommended as a
rough rule, even though it is appreciated that this could
lead to overdiagnosis of IgG4-RD (Okazaki et al., 2011;
Deshpande et al., 2012; Umehara et al., 2012b). Hence,
for most of the manifestations of IgG4-RD, specific cut-
off values for IgG4-positive cell infiltration and
IgG4/IgG-ratios have been developed (Deshpande et al.,
2012). 
If all the four listed criteria are met, a diagnosis of
IgG4-RD is highly suggested. If not all these criteria are
met, a diagnosis of IgG4-RD is still probable, but
additional non-microscopic criteria, particularly elevated
serum levels of IgG4 and proof of other organ
involvement of IgG4-RD, are necessary for the diagnosis
(Deshpande et al., 2012). 
Diagnosis and treatment of IgG4-RD
In the first study to show elevation of serum IgG4 in
AIP, the sensitivity of IgG4 was 90.9% compared to
70.5% for IgG (Hamano et al., 2001). The specificity of
IgG4 in differentiating between AIP and pancreatic
cancer was 98% (Hamano et al., 2001). Reported other
autoantibodies in another landmark study of type 1 AIP
were antinuclear antibody in 76%, anti-lactoferrin in
76%, anti-carbonic-anhydrase II in 59%, rheumatoid
factor in 29% and anti-smooth muscle antibody in 18%
(Okazaki et al., 2000). The sensitivity of serum
gammaglobulins was estimated 59.1% (Kawa and
Hamano, 2003). A few years later, elevation of serum
IgG4 was also reported in patients with Mukulicz
disease (MD) and later also in patients with other
manifestations of IgG4-RD (Yamamoto et al., 2004;
Masaki et al., 2009). Some of the other markers
mentioned above were later also found to be increased in
some patients with extrapancreatic manifestations of
IgG4-RD (Nishi et al., 2007, 2010; Masaki et al., 2009).
Also, hypergammaglobulinaemia, an increase of IgE,
hypocomplementaemia and the detection of immune
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Table 1. The different organ manifestations of IgG4-related disease
(IgG4-RD), listed successively as discussed in the text. 
Manifestations of IgG4-RD 
Type 1 autoimmune pancreatitis (IgG4-related pancreatitis)
IgG4-related sclerosing cholangitis (SC)
IgG4-related sialadenitis (including Küttner’s tumor)
IgG4-related thyroiditis (including fibrosing Hashimoto’s thyroiditis and 
Riedel’s thyroiditis)
IgG4-related retroperitoneal fibrosis (RF)
IgG4-related periaortitis
Multifocal fibrosclerosis
IgG4-related cervical sclerosis (syn. idiopathic sclerosing cervicitis, 
cervical fibrosclerosis)
IgG4-related inflammatory pseudotumor (IPT)
IgG4-related mastitis
IgG4-related prostatitis






IgG4-related orbital inflammatory pseudotumor
IgG4-related dacryoadenitis
IgG4-related pericarditis
Gastrointestinal reactive nodular fibrosing tumor
Sclerosing angiomatoid nodular transformation (SANT)
IgG4-related mesenteritis (sclerosing mesenteritis)
IgG4-related skin disease (cutaneous pseudolymphoma)
Nomenclature adapted from: Stone et al. (2012a). Recommendations
for the nomenclature of IgG4-related disease and its individual organ
system manifestations. Arthritis Rheum. 64, 3061-3067.
complexes can be employed in establishing the diagnosis
(Umehara et al., 2012a). Hence, the diagnosis can in
many instances be made based on serum IgG4 (cut-off
135 mg/dL) together with either typical histop-
athological findings or evidence of diffuse or focal
enlargement, or a massforming lesion in the respective
organ (Masaki et al., 2009; Zen and Nakanuma, 2010;
Umehara et al., 2012a). However, as serum IgG4 is not
elevated in all patients, serologically negative patients
can also be diagnosed with IgG4-RD, if there is strong
microscopic evidence (Okazaki et al., 2011; Umehara et
al., 2012a). Also, histology alone can provide the
diagnosis, but only if features (A), (B), (C) and (D)
mentioned above are noted (Okazaki et al., 2011;
Umehara et al., 2012a).
Most patients respond well to steroid treatment
(Stone et al., 2012b). However, if steroid treatment is
tapered too early or relapse occurs, another course of
steroids or low-dose steroid treatment for maintenance
therapy should be given (Masaki et al., 2009). In
difficult cases azathioprine, methotrexate or rituximab
have also been used in IgG4-RD (Khosroshahi et al.,
2010; Stone et al., 2012b). In some patients, it is urgent
to initiate steroid treatment, as irreversible organ damage
can otherwise occur. 
Malignancy in IgG4-RD
In all cases of IgG4-RD, it is of the utmost
importance to exclude a malignant neoplasm, even if
there is evidence of serum IgG4 elevation, because
serum IgG4 can also be increased in a minor number of
patients suffering from malignant disease in a variety of
organs (Ghazale et al., 2007; Raina et al., 2008;
Yamamoto et al., 2012). Also, tissue infiltration with
IgG4-RD itself is not specific, as Strehl et al. pointed out
(Strehl et al., 2011). They demonstrated significant
numbers of IgG4-positive cells and also elevated IgG4 to
IgG ratios in inflammatory lesions of the oral cavity
(Strehl et al., 2011). Furthermore, at other sites,
particularly in inflammatory bowel disease of the lower
gastrointestinal tract, synovitis and carcinomas,
sometimes high numbers of IgG4 positive cells were
observed, but a IgG4/IgG ratio above 0.4 was not noted
in these non-IgG4-RD conditions (Strehl et al., 2011).
However, the occurrence of storiform fibrosis or
obliterative phlebitis was not reported in this study.
Furthermore, in every case, a manifestation of
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Fig. 2. Characteristic histological findings in IgG4-related disease (IgG4-RD). A. A cartwheel-like, cellular and storiform fibrosis is shown (H&E). 
B. Obliterative phlebitis. Note that the arterial vessel located below the venous branch is without significant inflammation (H&E). C. Dense infiltration
with IgG4-positive cells (IgG4 immunostaining). D. IgG-positive cells slighly outnumber the IgG4-positive cells shown in Fig. 2C (IgG immunostaining).
sarcoidosis, granulomatosis with polyangiitis (formerly
called Wegener ’s granulomatosis), lymphoma or
inflammatory myofibroblastic tumor should be excluded
before establishing the diagnosis (Okazaki et al., 2011;
Smyrk, 2011; Umehara et al., 2012a). Of note, serum
IgG4 levels were slightly higher in granulomatosis with
polyangiitis patients compared to normal controls, and
MPO-ANCA IgG4-subclass antibodies may play a role
in the development of this disease (Holland et al., 2004;
Liu et al., 2008; Vaglio et al., 2012). Besides, for most of
the sites which can be affected in IgG4-RD, there are
organ-specific differential diagnoses which should be
ruled out before establishing the diagnosis. 
Malignancies prior to or after diagnosis of IgG4-RD
were noted in 10.4% in a 3-year-follow-up study of 104
IgG4-RD patients, and in 11.5% in a 5-year-follow-up
study of 63 surgically treated type 1 AIP patients
(Detlefsen et al., 2012; Yamamoto et al., 2012). Hence,
these data indicate that IgG4-RD patients may be at
increased risk for developing malignancies, and, until
more precise data on IgG4-RD are available, the
thorough search for malignancies during follow-up of
these patients is recommended (Yamamoto et al., 2012).
Organ manifestations of IgG4-related disease
In the following sections, some of the most
important manifestations of IgG4-RD will be addressed,
with special emphasis on their microscopic features. 
Type 1 autoimmune pancreatit is (IgG4-related
pancreatitis)
Clinically, AIP patients complain of abdominal pain,
anorexia and jaundice (Kamisawa et al., 2003c; Kleeff et
al., 2006; Church et al., 2007). Macroscopically, AIP
sometimes mimics pancreatic cancer because it in some
instances forms a tumor-like mass in the pancreatic head,
body or tail (Zamboni et al., 2000; Klöppel et al., 2007;
Esposito et al., 2008; Detlefsen and Drewes, 2009;
Zamboni et al., 2009). A follow-up study on surgically
treated AIP patients reported the inflammatory lesion in
the pancreatic head in 76%, pancreatic body in 6%, the
tail in 14% and diffusely in the whole gland in 3% of
type 1 AIP (Detlefsen et al., 2012). However, the focal
type of AIP will naturally occur more frequently in
studies based on pancreatic resection specimens, because
most of these specimens are resected due to suspected
pancreatic cancer. In studies based on a mix of
conservatively and surgically treated type 1 AIP patients,
roughly 40% show diffuse swelling of the pancreas
(Kamisawa et al., 2011). The typical computed
tomography (CT) presentation of AIP is a diffuse,
sausage-like enlargement of the pancreas with delayed
enhancement (Chari et al., 2009). Pseudocysts and
calculi are less frequently noted compared to alcoholic
chronic pancreatitis (Ectors et al., 1997; Notohara et al.,
2003; Zamboni et al., 2004). 
Periductal infiltration with lymphocytes and plasma
cells is observed in both types of AIP (Fig. 3A).
Microscopic features of type 1 AIP can aid as a basis for
the diagnosis also in pancreatic core needle biopsy
specimens (Zamboni et al., 2004; Chari et al., 2006;
Detlefsen et al., 2009). The feature that usually is not
observed in IgG4-related pancreatitis but abundantly in
the non-IgG4-related type 2 AIP is the granulocytic
epithelial lesion (GEL) (Fig. 3B) (Zamboni et al., 2004).
This lesion is characterized by penetration of
neutrophilic granulocytes through the duct epithelium
and their accumulation in the duct lumen (Zamboni et
al., 2004). 
The differential diagnosis of AIP versus pancreatic
cancer is important, because type 1 AIP as the prototype
of an IgG4-related disease responds well to steroid
treatment. Hence, clinicians should try to differentiate
AIP from pancreatic cancer before surgery is performed,
even though it of course would be detrimental to treat a
patient with a resectable pancreatic carcinoma with
steroids. In a core needle biopsy study including 26
patients with AIP, 45% showed GELs and 38% had
569
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Fig. 3. A. Periductal lymphoplasmacytic infiltration in IgG4-related autoimmune pancreatitis (H&E). B. Granulocytic epithelial lesion in non-IgG4-related
AIP (H&E).
infiltration with IgG4-positive cells (Detlefsen et al.,
2009). The detection of GELs was indicative of type 2
AIP (Detlefsen et al., 2009). The following microscopic
features were assessed: GELs, >10 IgG4-positive plasma
cells/ high power field (HPF), >10 eosinophilic
granulocytes/HPF, cellular fibrosis with inflammation,
lymphoplasmacytic infiltration and venulitis (Detlefsen
et al., 2009). All biopsies that showed four or more of
the six features were obtained from 21/26 AIP patients.
The biopsies from 14 non-AIP patients, taken from
lesions showing peritumoral pancreatitis or alcoholic
pancreatitis, had only three or fewer of the features
(Detlefsen et al., 2009). Hence, these data indicate that
the presence of four of the six criteria can be considered
as diagnostic for AIP in patients lacking characteristic
features of pancreatic cancer clinically, serologically and
radiologically. Similarly, the current international
consensus diagnostic criteria (ICDC) recommend that
for a definitive histological diagnosis of type 1 AIP at
least 3 of 4 features (marked lymphoplasmacytic
infiltration, storiform fibrosis, obliterative phlebitis and
IgG4-positivity) should be present in a core needle
biopsy (Shimosegawa et al., 2011). However, it is of the
utmost importance to exclude pancreatic cancer in core
needle biopsies before suggesting AIP. If necessary,
immunohistochemical stains for markers such as
SMAD4, monoclonal CEA, MUC1, p53, Ki67 or S100P
can be of valuable help, particularly when considering
well-differentiated ductal adenocarcinoma accompanied
by inflammation (Klöppel and Adsay, 2009). Of note,
several reports of pancreatic cancer occurring
synchronously or metachronously in AIP patients are on
record (Inoue et al., 2006; Kamisawa et al., 2006a; Fukui
et al., 2008; Witkiewicz et al., 2008; Motosugi et al.,
2009). Also, non-Hodgkin lymphoma has been reported
in an AIP patient (Takahashi et al., 2009). 
IgG4-related sclerosing cholangitis
IgG4-related sclerosing cholangitis (IgG4-related
SC) is the most important and most frequently observed
extrapancreatic manifestation IgG4-RD in type 1 AIP
patients (Kamisawa et al., 2003c, 2009; Sah et al., 2010;
Detlefsen et al., 2012). It shows most of the
characteristic features of IgG4-RD, even though the
storiform fibrosis sometimes is not prominent (Fig. 4).
The most important differential diagnosis is primary
sclerosing cholangitis (PSC) (Mendes and Lindor, 2010).
IgG4-related SC has mostly been observed in adults,
while PSC is also sometimes seen in children (Schrumpf
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Fig. 4. IgG4-related sclerosing cholangitis. A and B. Cross-section of the extrapancreatic portion of the common bile duct showing stenosis due to
diffuse lymphoplasmacytic infiltration and fibrosis (H&E). C. Strong infiltration of IgG4-positive cells around peribiliary tubular glands of the bile duct wall
(IgG4 immunostaining). D. Core needle biopsy specimen showing infiltration of the distal common bile duct mucosa with lymphoplasmacytic
inflammatory cells (CD79a immunostaining).
and Boberg, 2001; Mendes and Lindor, 2010). While
IgG4-related SC shows association with other
manifestations of IgG4-RD, PSC shows concomitant
inflammatory bowel disease in 80% of cases (Schrumpf
and Boberg, 2001). Besides, IgG4-related SC shows
frequently elevated serum IgG4 while 80% of PSC
patients show elevated pANCA antibodies, even though
a small subgroup of PSC patients also have elevated
serum IgG4 levels (Mendes et al., 2006; Mendes and
Lindor, 2010). While PSC occurs in both the extra- and
intrahepatic bile ducts and is often diffusely distributed,
IgG4-related SC is mainly located in the hilum of the
liver and in the extrahepatic bile ducts (Björnsson et al.,
2007; Mendes and Lindor, 2010; Zen and Nakanuma,
2012). In PSC, fibro-obliterative lesions of the bile ducts
as well as ulceration of the mucosa and sometimes also
xanthogranulomatous inflammation are often
appreciated, while obliterative phlebitis, dense fibrosis
(Fig. 4A-B) and strong infiltration with IgG4-positive
cells (Fig. 4C) are more characteristic of IgG4-related
SC (Björnsson et al., 2007; Silveira and Lindor, 2008;
Mendes and Lindor, 2010; Zen and Nakanuma, 2012).
Recently, IgG4-negative cases of SC not fitting into the
PSC category have been noted (Aoki et al., 2003; Lee et
al., 2005; Fujita et al., 2010; Zen et al., 2012). These
cases showed strong lymphoplasmacytic infiltration and
abundance of lymphoid follicles with activated germinal
centers and were called "follicular cholangitis".
Obliterative phlebitis and a storiform type of fibrosis as
well as IgG4-positivity in the tissue were absent (Fujita
et al., 2010; Zen et al., 2012). Zen also noted this type of
inflammation in the pancreas in two patients (Zen et al.,
2012). The responsiveness to steroids of follicular
cholangitis and pancreatitis remains to be elucidated
(Zen et al., 2012).
IgG4-related sialadenitis
Involvement of the salivary glands was noted in 14%
of resected type 1 AIP, thereby the second most common
site of extrapancreatic organ involvement in IgG4-
related AIP (Detlefsen et al., 2012). IgG4-related
sialadenitis probably corresponds to the unilateral
swelling of the submandibular gland described by
Küttner in 1896 (Küttner, 1896; Kitagawa et al., 2005;
Geyer et al., 2010; Laco et al., 2011). Macroscopically,
IgG4-related sialadenitis sometimes involves the entire
submandibular or parotid gland, but more often well
circumscribed lesions involving between 30% and 80%
of the parenchyma are noted (Geyer et al., 2010).
Obliterative phlebitis was noted in roughly 50% of
Geyer ’s 13 cases (Geyer et al., 2010). Cellular
interlobular fibrosis and florid lymphoid follicle
hyperplasia are observed in most cases (Geyer et al.,
2010). The number of IgG4-positive cells usually ranges
from 120 to 230 per HPF, and the mean IgG4 to IgG
ratio ranges from 0.7 to 0.85 (Fig. 5A-B) (Kitagawa et
al., 2005; Geyer et al., 2010). Laco and colleagues
reported a lower cut-off of 50 IgG4-positive cells per
HPF and an IgG4 to IgG cell ratio of at at least 0.40 as
useful for the differentiation of IgG4-related sialadenitis
from chronic sialadenitis, not otherwise specified (Laco
et al., 2011). 
Sialolithiasis-related sialadenitis can also show
infiltration with lymphocytes and plasma cells, but the
inflammatory foci are typically patchily distributed
(Seifert et al., 1986a). Furthermore, there are only few
IgG4-positive cells, IgG4 to IgG ratios are usually low,
and obliterative phlebitis is not characteristic (Kitagawa
et al., 2005; Geyer et al., 2010). Sometimes the calculi
lead to erosion or squamous metaplasia of the epithelium
(Seifert et al., 1986b). In Sjögren’s syndrome, the
fibrosis is less prominent compared to IgG4-related
sialadenitis, while atrophy seems to be more common
(Seifert et al., 1986a). In contrast to initial hypotheses,
Sjögren’s syndrome seems not to be part of IgG4-RD,
and IgG4 stains are typically negative or only weakly
positive (Kitagawa et al., 2005; Geyer et al., 2010). As
in most cases of IgG4-RD, lymphoma has to be
considered in the differential diagnosis. This is of
particular importance if several salivary glands and/or
also the lacrimal glands are involved. Such a scenario is
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Fig. 5. IgG4-related sialadenitis. A. Intralobular infiltration of IgG4-positive cells (IgG4 immunostaining). B. A large proportion of the IgG4-positive cells
shown in Figure 5A also stain for IgG (IgG immunostaining).
suggestive of multifocal IgG4-RD, but also lymphoma,
particularly mucosa-associated lymphoid tissue (MALT)
lymphoma, has to be considered. This is highlighted by
the fact that the original report of Mikulicz’s disease,
often referred to in the literature as a benign, chronic
inflammatory disease of the salivary and lacrimal glands,
has in retrospect been interpreted as a MALT lymphoma
by some authors, and it seems that the eponym
Mikulicz’s disease is better no longer used (Mikulicz,
1892; Ihrler and Harrison, 2005; Harrison and
Rodriguez-Justo, 2011; Laco et al., 2011; Himi et al.,
2012).
IgG4-related thyroiditis
The observation that around 25% of patients with
AIP also show hypothyroidism, often accompanied by
antibodies to thyreoglobulin, preceded immunohisto-
chemical studies of IgG and IgG4 expression in resected
thyroid tissue from patients with Hashimoto’s thyroiditis
(Komatsu et al., 2005; Hamano et al., 2006). Using a
threshold of 20 IgG4-positive cells per HPF and an
IgG4/IgG ratio of at least 30%, Li et al. separated
resection specimens with Hashimoto’s thyroiditis into
IgG4-positive and IgG4-negative cases (Li et al., 2009).
They also showed that IgG4-positive plasma cell
infiltrates were associated with a more fibrotic type of
Hashimoto’s and a shorter interval between onset of
disease and surgery (Li et al., 2010). In a series of 70
Hashimoto’s thyroiditis cases, 27% were IgG4-positive
(Li et al., 2010). At microscopy, storiform fibrosis and
diffuse lymphoplasmacytic infiltration (Fig. 6A) are
noted. Also obliterative phlebitis is a feature of IgG4-
related thyroiditis (Fig. 6B) (Dahlgren et al., 2010).
The differention of the fibrosing variant of
Hashimoto’s thyroiditis from Riedel’s thyroiditis can be
difficult (Katz and Vickery, 1974; Harach and Williams,
1983; Dahlgren et al., 2010). Riedel’s thyroiditis forms a
firm and "woody" palpable mass, which extends into the
surrounding structures (Hennessey, 2011). The condition
was named after Bernhard Riedel, who published his
cases in the last decade of the 19th century (Riedel,
1896, 1897). At microscopy, there is a dense and hyaline
fibrosis and diffuse lymphoplasmacytic and eosinophilic
infiltration (Harach and Williams, 1983). Obliterative
phlebitis seems to be more frequent in Riedel’s
thyroiditis compared to Hashimoto’s thyroiditis (Katz
and Vickery, 1974; Harach and Williams, 1983; Li et al.,
2009; Dahlgren et al., 2010; Hennessey, 2011). For most
authors, it is essential to demonstrate fibrosis and/or
inflammation outside the thyroid capsule to establish a
diagnosis of Riedel’s thyroiditis (Hennessey, 2011).
However, Riedel’s thyroditis is extremely rare. In a
study on 56.700 thyroidectomies performed at the Mayo
Clinic between 1920 and 1984, the frequency of Riedel’s
thyroiditis was only 0.06%, and between 1976 and 2008,
only 21 certain surgical cases of Riedel’s thyroiditis
were observed retrospectively at this institution (Hay,
1985; Fatourechi et al., 2011). Recently, Riedel’s
thyroiditis has been linked to IgG4-RD (Dahlgren et al.,
2010). The exact relationship between Riedel’s
thyroiditis and fibrosing Hashimoto’s thyroiditis,
however, remains to be established, but it is possible that
further studies of IgG4-positive cases of both entities
will gain further insight (Hennessey, 2011).
IgG4-related retroperitoneal fibrosis 
Albarran described more than a century ago the
surgical treatment of idiopathic retroperitoneal fibrosis
(RF)-related ureteral obstruction (Albarran, 1905).
However, it was not before 1948, when Ormond
published two cases of idiopathic RF causing bilateral
ureteral obstruction, that this condition became more
widely known as an acknowledged disease entity
(Ormond, 1948). Since that time, several advances have
been made in the understanding and treatment of RF
(Vaglio et al., 2006). Microscopically, early-stage RF
572
IgG4-related disease
Fig. 6. IgG4-related thyroiditis. A. Thyroid follicles surrounded by lymphoplasmacytic inflammation and fibrosis are shown (H&E). B. Inflammation and
storiform fibrosis surrounding a vessel with obliterative phlebitis (Verhoeff elastin).
shows a highly vascular stroma with many lymphocytes
and plasma cells, with numerous fibroblasts interspersed
between bundles of collagen. Later stages show a
pronounced fibrosis with only scattered inflammatory
cells and sometimes calcifications (Vaglio et al., 2006).
Several reports point out that a substantial number of RF
cases are part of IgG4-RD (Yamashita et al., 2008; Zen
et al., 2009b). Yamashita found that patients with RF and
associated AIP had between 60 and 580 IgG4-positive
cells per HPF with IgG4 to IgG ratios between 66% and
80%, while most patients with isolated RF had less than
50 IgG4-positive cells per HPF (Yamashita et al., 2008).
Zen examined core needle biopsies from RF patients and
separated them into IgG4-positive and IgG4-negative
RF. The former had IgG4 to IgG ratios between 35% and
76% and frequent occurence of lymphoid follicles and
obliterative phlebitis. The latter had IgG4 to IgG ratios
between 0% and 10%, and lymphoid follicles as well as
obliterative phlebitis were sparse (Zen et al., 2009b). He
suggested that the IgG4-negative cases may be either
burnt out IgG4-RD or that only a subgroup of RF
patients belong to the spectrum of IgG4-RD (Zen et al.,
2009b). It is recommended that at least 30 IgG4-positive
cells per HPF should be present to suggest the diagnosis
of IgG4-related RF (Deshpande et al., 2012).
IgG4-related periaortitis
Walker et al. coined the term inflammatory
abdominal aortic aneurysm (AAA) in 1972 (Walker et
al., 1972). Among 187 resected AAA patients, 19
showed thickening of the aneurysm walls and periaortic
adhesions (Walker et al., 1972). At microscopy, these
cases had marked fibrosis and lymphoplasmacytic
inflammation in the adventitia and/or outer media.
Lymphoid aggregates, lymphoid follicles and
perivascular inflammatory infiltrates were also noted
(Walker et al., 1972). Inflammatory AAA often coexists
with RF, as the fibroinflammatory lesions may extend
into the retroperitoneal periaortic tissue (Leu, 1990).
Inflammatory AAA can be subclassified, depending on
the severity of IgG4-positive cell infiltration (Kasashima
et al., 2009). Higher IgG4 to IgG ratios and more
pronounced obliterative phlebitis are observed in IgG4-
related periaortitis compared to non-IgG4-related
inflammatory AAA (Kasashima et al., 2009). It is
recommended that at least 50 IgG4-positive cells per
HPF should be present to suggest the diagnosis of IgG4-
related inflammatory AAA (Deshpande et al., 2012).
Multifocal fibrosclerosis and idiopathic cervical sclerosis
The systemic entity known in the literature as
multifocal fibrosclerosis was put forward by Comings
and coworkers in 1967, but their paper was anticipated
by a few publications focusing on inflammatory
fibrosing mediastinitis causing obstruction of the
superior vena cava and its association with RF,
inflammatory pseudotumor of the orbit and Riedel's
thyroiditis (Tubbs, 1946; Barrett, 1958; Comings et al.,
1967). Comings reported orbital inflammatory
pseudotumor, sclerosing cholangitis, RF, mediastinal
fibrosis and Riedel's thyroiditis in two brothers who had
consanguinous parents (Comings et al., 1967). Also,
idiopathic cervical fibrosis has been linked to multifocal
fibrosclerosis (Rice et al., 1975). As mentioned in the
respective sections, in most of these entities a significant
proportion of cases is now known to be part of IgG4-
RD, and this also holds for idiopathic cervical fibrosis
(Cheuk et al., 2010). Hence, it seems that there is at least
a partial overlap between multifocal fibrosclerosis and
IgG4-RD (Dahlgren et al., 2010).
IgG4-related inflammatory pseudotumor
Inflammatory pseudotumors (IPT) have traditionally
been defined as mass-forming, non-neoplastic lesions in
various organs and at various sites, particularly in the
lung, liver and abdominal soft tissue (Umiker and
Iverson, 1954; Anthony, 1993). IPT produces grey or
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Fig. 7. Prostatic core needle biopsy showing IgG4-related prostatitis. A. Lymphoplasmacytic infiltration and a slightly storiform fibrosis is appreciated
(H&E). B. Many of the plasma cells are IgG4-positive (IgG4 immunostaining).
whitish tumor-like lesions (Palazzo and Chang, 1993).
At microscopy, a proliferation of fibroblasts and
myofibroblasts accompanied by lymphocytes, plasma
cells, eosinophils and a swirling fibrosis is noted
(Anthony, 1993; Palazzo and Chang, 1993). After
identification of the myofibroblast as the main
proliferating cell, cytogenetic banding studies showing
that unequivocal clonal mutations are present in some
IPTs, and after recognition of chromosomal
rearrangements involving the ALK receptor tyrosin-
kinase locus region (chromosome band 2p23), the term
"inflammatory myofibroblastic tumor" has been
increasingly used for these tumors (Treissman et al.,
1994; Coffin et al., 1995, 1998; Sciot et al., 1997; Griffin
et al., 1999). However, it is still believed that not all IPTs
are neoplastic IMTs (Yi and Aubry, 2010). Some of these
true IPTs have been shown to belong to the IgG4-RD
entity, for example in the breast, liver, lung and spleen
(Zen et al., 2005a,b, 2007a,b; Cornell et al., 2007; Kuo
et al., 2009). Yamamoto et al. compared ALK-positive
IMT cases with typical cases of IgG4-RD (Yamamoto et
al., 2009). Patients with IMT were younger and showed
aberrant expression of ALK in roughly 70% of the cases,
but lacked obliterative phlebitis and significant
infiltration with IgG4-positive cells. On the other hand,
no aberrant ALK expression was found in IgG4-RD
(Yamamoto et al., 2009). Whether ALK- and IgG4-
negative IPTs represent an entity on their own remains to
be elucidated. 
IgG4-related mastitis
IgG4-RD of the breast presents typically as a uni- or
bilateral mass-forming lesion, and breast cancer is an
important initial differential diagnosis (Zen et al., 2005a;
Cheuk et al., 2009a; Ogiya et al., 2010). At microscopy,
there is a dense lymphoplasmacytic infiltrate which can
mimic lymphoma. The fibrosis is of the more patchy
type but can also show a storiform pattern. There is
atrophy of the normal breast parenchyma (Zen et al.,
2005a; Cheuk et al., 2009a; Ogiya et al., 2010). The
differential diagnosis versus lymphocytic mastitis is
mainly based on the fact that this type of mastitis mainly
shows infiltrates of small lymphocytes with only few
plasma cells and that the fibrosis is of the keloid type
(Valdez et al., 2003). In IgG4-related mastitis, there are
many IgG4-positive cells. IgG4/IgG ratios between 0.5
and 0.85, and total numbers of 270 to 500 IgG4-positive
cells per HPF were reported (Cheuk et al., 2009a). Some
of the cases diagnosed in the past as granulomatous
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Fig. 8. IgG4-related lung disease, nodular type. A. Fibrosis is accompanied by lymphocytes, plasma cells and histiocytes (H&E). B. Interspersed lung
epithelium at the periphery of the lesion is noted (cytokeratin KL1 immunostaining). C. Numerous myofibroblasts are shown (alpha-smooth muscle actin
immunostaining). D. Many of the plasma cells express IgG4 (IgG4 immunostaining).
mastitis seem to fit well in the category of IgG4-related
mastitis (Ogura et al., 2010). In some of the published
cases, histology was based on a core needle biopsy or
excision biopsy of the breast, while the diagnosis in
others was established postoperatively, on a lumpectomy
specimen (Zen et al., 2005a; Cheuk et al., 2009a; Ogiya
et al., 2010). 
IgG4-related prostatitis
Several reports of IgG4-related prostatitis are on
record (Yoshimura et al., 2006; Nishimori et al., 2007).
Uehara et al. examined six patients with AIP-associated
prostatitis and compared their pathologic features with
10 patients who were clinically suspicious for prostatic
cancer but only had focal inflammation without
carcinoma (Uehara et al., 2008). In IgG4-related
prostatitis, lymphoplasmacytic infiltration without
granuloma formation, scattered eosinophils, obliterative
phlebitis, atrophy of the parenchyma and fibrosis were
appreciated (Fig. 7A). There are numerous IgG4-positive
cells and IgG4/IgG ratios between 0.5 and 0.7 (Fig. 7B)
(Uehara et al., 2008). In unspecific prostatitis, the
inflammatory infiltrate also consisted of lymphocytes
and plasma cells, but they were focally distributed in the
gland, and fibrosis and IgG4-positive cells were sparse,
while eosinophilic infiltration was lacking (Uehara et al.,
2008). 
IgG4-related lung and pleural disease
IgG4-related lung disease does not always produce
symptoms, but it can give rise to cough, hemoptysis,
dyspnea and pleural effusion (Ryu et al., 2012). At
imaging, IgG4-related lung disease may present as
solitary or multiple nodules or as peribronchial
consolidation (Ryu et al., 2012). Histologically, a solid
nodular pattern, a bronchovascular pattern, an alveolar
interstitial pattern or pleural disease can be encountered
(Zen et al., 2009a). The solid nodular pattern
corresponds to the IgG4-related IPT of the lung and is
typically located either peripherally or in the hilus region
(Fig. 8) (Zen et al., 2005b, 2009a). In the
bronchovascular type, the lymphoplasmacytic infiltrate
is distributed along the bronchovascular bundles and
interlobular septa, and in the alveolar interstitial type in
the alveolar interstitium. In pleural IgG4-RD,
fibroinflammatory thickening of the visceral or parietal
pleura is noted (Zen et al., 2009a). Obliterative phlebitis
was more frequent in the solid nodular and pleural types.
At least 50 IgG4-positive cells per HPF should be
present to suggest the diagnosis of IgG4-related lung
disease in surgical specimens, and at least 20 IgG4-
positive cells/HPF in lung biopsies (Deshpande et al.,
2012).
IgG4-related lymphadenopathy
Already in one of the first descriptions of AIP, it was
noted that some of the patients had enlarged
peripancreatic and intraabdominal lymph nodes
(Kawaguchi et al., 1991). Cheuk and Chan suggested
that IgG4-related lymphadenopathy may only reflect the
immune disturbance that is causing IgG4-RD (Cheuk
and Chan, 2010). Five different histologic patterns of
IgG4-related lymphadenopathy have been observed
(Cheuk et al., 2008; Sato et al., 2009, 2011; Cheuk and
Chan, 2010). Type I has been called the multicentric
Castleman disease-like type, owing to its similarity to
this condition (Cheuk et al., 2008). Hyperplastic
lymphoid follicles with frequent penetration by
hyalinized blood vessels, numerous high endothelial
venules and many IgG4-positive plasma cells in the
interfollicular region are appreciated (Fig. 9).
Multicentric Castleman disease, however, lacks
increased IgG4-positivity in the tissue (Sato et al., 2009).
IgG4-related lymphadenopathy type II shows unspecific
reactive hyperplasia, with varying interfollicular
plasmacytosis (Cheuk et al., 2008). Type III is
characterized by interfollicular expansion and sparse or
atrophic lymphoid follicles (Cheuk et al., 2008). In type
IV, progressive transformation of lymphoid follicles is
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Fig. 9. IgG4-related lymphadenopathy, type I. A. Hyperplastic lymphoid follicles and an interfollicular zone containing high endothelial venules and
numerous lymphocytes and plasma cells is shown (H&E). B. Strong interfollicular infiltration with IgG4-positive cells (IgG4 immunostaining).
noted, and some lymphoid follicles contain plasma cells
in their germinal centers (Sato et al., 2009). Type V has
been called nodal IPT-like, due to the focal replacement
of the nodal tissue with fibrosis, accompanied by
lymphocytes, plasma cells and eosinophils (Cheuk and
Chan, 2010; Sato et al., 2011). An IgG4/IgG-ratio
between 45% and 73% and at least 100 IgG4-positive
cells should be noted per HPF for a given case to be
highly suggestive of IgG4-related lymphadenopathy
(Sato et al., 2009; Deshpande et al., 2012).
IgG4-related kidney disease
IgG4-related kidney disease often results in a rather
mild impairment of kidney function. At CT, sometimes
multiple renal low-attenuation lesions are observed
(Sahani et al., 2004; Uchiyama-Tanaka et al., 2004). Of
note, IgG4 is the predominant component of glomerular
subepithelial immune deposits in membranous
nephropathy (Imai et al., 1997). Saeki et al. suggested
that membranous nephropathy may represent one of the
renal diseases appearing secondary to IgG4-RD, like
tubulointerstitial nephritis (TIN) (Saeki et al., 2009a).
TIN secondary to IgG4-RD shows by definition a
fibroinflammatory interstitial infiltrate with varying
grades of (not allways storiform) fibrosis and more than
10 IgG4-positive cells per HPF, while obliterative
phlebitis is not so common, particularly in core needle
biopsies (see also Figure 10) (Cornell et al., 2007;
Raissian et al., 2011; Deshpande et al., 2012). In a
significant proportion of cases with TIN secondary to
IgG4-RD, there is deposition of complement C3, IgG
and/or IgG4 along the tubular basement membrane
(Cornell et al., 2007; Raissian et al., 2011; Deshpande et
al., 2012). Storiform fibrosis and obliterative phlebitis do
not have to be present for the diagnosis. A plasma cell-
rich TIN with increased IgG4-positive cells is the main
diagnostic criterion, together with at least one of the
criteria imaging, serology and other organ involvement
(Cornell et al., 2007; Raissian et al., 2011; Deshpande et
al., 2012).
Other manifestations of IgG4-RD
Figure 1 gives a schematic illustration of the main
manifestations of IgG4-RD. IgG4-related hepatopathy
occurs most often in patients with IgG4-related SC and
appears at imaging as nodular lesions (Nakanuma and
Zen, 2007). Of note, an IgG4-positive subtype of
autoimmune hepatitis has been described (Chung et al.,
2010; Umemura et al., 2011). Nodular lesions show
microscopic features of the hepatic type of inflammatory
pseudotumor (Zen et al., 2007b; Naitoh et al., 2009). 
IgG4-related hypophysitis (Wong et al., 2007;
Shimatsu et al., 2009), IgG4-related pachymeningitis
(Chan et al., 2009), IgG4-related orbital inflammatory
pseudotumor (Plaza et al., 2011) and IgG4-related
dacryoadenitis (Takahira et al., 2007) are other important
manifestations. Also, constrictive pericarditis (Sugimoto
et al., 2008; Sakamoto et al., 2012), gastrointestinal
reactive nodular fibrosing tumor (Chetty et al., 2011),
sclerosing angiomatoid nodular transformation (SANT)
(Kashiwagi et al., 2008; Nagai et al., 2008; Kuo et al.,
2009), sclerosing mesenteritis (Chen and Montgomery,
2008; Nomura et al., 2011) and a subgroup of cutaneous
pseudolymphoma (Cheuk et al., 2009b; Khosroshahi et
al., 2011a) have been added to the spectrum of IgG4-RD.
Pathogenesis of IgG4-RD
The pathogenesis of IgG4-RD has not yet been fully
elucidated, but autoimmune mechanisms are suggested
(Stone et al., 2012b). It is still unclear whether IgG4
itself plays a role in the pathogenesis. As the human
subclasses of IgG are numbered due to their plasma
concentration, IgG4 is the least common antibody. IgG1,
on the other hand, represents more than 50% of the total
IgG (Pezzilli and Morselli-Labate, 2010). IgG2
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Fig. 10. Tubulointerstitial nephritis (TIN) secondary to IgG4-RD. A. Diffuse lymphoplasmacytic infiltration between the tubuli and glomeruli. Atrophy af
the renal tissue and fibrosis are noted (H&E). B. TIN with less pronounced fibrosis than in Fig. 10A. IgG4-positivity of numerous plasma cells (IgG4
immunostaining).
antibodies are the main source of antibodies to bacterial
polysaccharides, while IgG4 antibodies are mainly
related to allergen-induced antibody production (van der
Giessen et al., 1976). In IgG4-RD, also total IgG, IgG1,
IgG2 and IgE are increased (Masaki et al., 2009; Taguchi
et al., 2009). IgM and IgA, on the other hand, are often
decreased, but elevated in some of the diseases which
have to be considered in the differential diagnosis
(Masaki et al., 2009; Taguchi et al., 2009). IgG4
antibodies do not usually precipitate and behave like
monovalent antibodies (van der Zee et al., 1986).
However, biochemically, they are best described as
hetero-bivalent antibodies, because they tend to
interchange one of the two heavy-light chain pairs with
the heavy-light chain pair of another molecule, resulting
in two different antigen-combining sites (van der Neut et
al., 2007). In pemphigus vulgaris, IgG4 antibodies to
desmoglein, the autoantigen which triggers this disease,
play a major role at least in its inital phase (Stanley and
Amagai, 2006). Of note, monoclonal IgG4 proteins in
myeloma patients show the capacity to act like
rheumatoid factor (Cohen et al., 1987). Kawa et al.
elucidated whether the polyclonal IgG4 from the serum
of AIP patients also acts like rheumatoid factor
regarding the ability to recognitize the constant portion
of IgG through its own variable segment (Kawa et al.,
2008). They found, however, that IgG4 binds to the
constant portion of IgG using its own constant portion
(Kawa et al., 2008). Hence, it is yet unclear whether
IgG4 acts autoantibody-like in IgG4-RD (Kawa et al.,
2008). 
Several disease-related antibodies have been
reported in IgG4-related pancreatitis, for example
antibodies to lactoferrin, carbonic anhydrase-II and
pancreatic secretory trypsin inhibitor (Kino-Ohsaki et
al., 1996; Okazaki et al., 2000; Asada et al., 2006; Löhr
et al., 2010). Amylase-alpha-2A and heat-shock protein-
10 antibodies are also elevated in some AIP patients, and
most of the antibodies just mentioned belong to the IgG1
subclass. Furthermore, some of these antigens are
expressed in the ductal cells of several exocrine organs
in which IgG4-RD has been described (Okazaki et al.,
2000; Uchida et al., 2000; Nishimori et al., 2005; Asada
et al., 2006; Nishi et al., 2007; Endo et al., 2009;
Frulloni et al., 2009; Takizawa et al., 2009). Hence, it is
tempting to speculate that these antigens may trigger the
disease. 
Increased circulating immune complexes
accompanied by hypocomplementaemia and tissue
deposition of C3, IgG and IgG-subclasses, including
IgG4, were observed in the kidneys and pancreata from
IgG4-RD patients (Deshpande et al., 2006; Cornell et al.,
2007; Saeki et al., 2009b; Detlefsen et al., 2010;
Yamamoto et al., 2010). However, IgG4 is not able to
activate complement by the classical pathway, and data
indicate that the classical pathway of complement
activation through IgG1 possibly plays a more important
role in the development of AIP than mannose-binding
lectin or alternative pathways through IgG4 (Muraki et
al., 2006). Interstingly, experiments in mice showed that
non-complement activating subclasses of antibodies can
synergize with other IgG subclasses to activate
complement through the lectin pathway (Murata et al.,
2007). Because IgG4 is bound to the constant portion of
IgG1 via its own constant portion in AIP, it may
contribute to the clearance of immune complexes or
even to the prevention of formation of large immune
complexes by blocking those effector functions of IgG1
that are mediated through the constant portion of IgG1
(Kawa et al., 2008; Okazaki et al., 2011). 
While early studies suggested a predominance of
CD4-positive T helper (Th)1 cells over Th2 cells in AIP
(Okazaki et al., 2000) and Mikulicz’s disease
(Yamamoto et al., 2005), the immune reaction in type 1
AIP and IgG4-related sclerosing cholangitis was later
reported to be mainly based on Th2 cells and
CD4+CD25+Foxp3 regulatory cells (Zen et al., 2007a).
Okazaki and colleagues recently summarized their
unifying hypothesis on the pathogenesis of IgG4-RD
(Okazaki et al., 2011): In early stages of IgG4-RD,
autoantigens may contribute to a decrease in the
suppressive effect of naïve natural regulatory T cells.
Afterwards, a Th1-type immune response may lead to an
increase of the proinflammatory cytokines interferon-
gamma, interleukin (IL)-2 and TNF-alpha (Kroemer et
al., 1996; Okazaki et al., 2011). According to Okazaki’s
hypothesis, Th2-type immune responses, based on the
secretion of IL-4, -5 and -10, may then upregulate IgG,
IgG4 and autoantibodies. The latter may then contribute
to the progression of the disease (Kroemer et al., 1996;
Okazaki et al., 2011). Upregulation of transforming
growth factor ß, amongst others, seems to contribute to
fibrogenesis during later stages of IgG4-RD (Detlefsen
et al., 2008; Okazaki et al., 2011). 
Conclusion
IgG4-related disease is a rapidly evolving
fibroinflammatory disease occurring at multiple sites of
the body. It is important for the pathologist to be familiar
with the characteristic microscopic features of this
disease because many patients initially are suspected of
suffering from malignancy. IgG4-RD patients, however,
do not need surgery in most cases. The characteristic
histological features of IgG4-RD are well recognized,
but contrasted by the need for a better understanding of
the etiology, pathophysiology and long-term outcome of
this systemic condition.
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